Deciphera Pharmaceuticals, Inc.

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting

Deciphera Announces the Opening of a New Office in Zug, Switzerland

Deciphera Announces Multiple Data Presentations at the Connective Tissue Oncology Society (CTOS) Annual Meeting 2025

Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 2025

Deciphera Receives European Commission Approval of ROMVIMZA™ (vimseltinib) for the Treatment of Tenosynovial Giant Cell Tumor (TGCT)

Deciphera Announces Positive CHMP Opinion for ROMVIMZA™ (vimseltinib) for the Treatment of Tenosynovial Giant Cell Tumor (TGCT)

U.S. FDA Grants Full Approval of Deciphera's ROMVIMZA™ (vimseltinib) for the Treatment of Symptomatic Tenosynovial Giant Cell Tumor (TGCT)

European Medicines Agency Accepts Deciphera's Marketing Authorization Application for Vimseltinib for Treatment of Patients with Tenosynovial Giant Cell Tumor (TGCT)

Deciphera Pharmaceuticals Announces Oral Presentation of Results from MOTION Pivotal Phase 3 Study of Vimseltinib in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the 2024 ASCO Annual Meeting and Online Publication in The Lancet

Deciphera's (DCPH) Shares Surge 74.3% in a Month: Here's Why

Here's What Key Metrics Tell Us About Deciphera Pharmaceuticals (DCPH) Q1 Earnings

Deciphera Pharmaceuticals, Inc. (DCPH) Reports Q1 Loss, Misses Revenue Estimates

DECIPHERA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Deciphera Pharmaceuticals, Inc. - DCPH

Japan's Ono Pharma says $2.4 bln Deciphera purchase 'first step' for global expansion

INVESTIGATION: The M&A Class Action Firm Announces An Investigation of Deciphera Pharmaceuticals, Inc. - DCPH

ONO to buy Deciphera Pharmaceuticals at a huge premium

ONO to buy Deciphera Pharmaceuticals at a huge premium

Why Is Deciphera Pharmaceuticals (DCPH) Stock Up 72% Today?

Shareholder Alert: Ademi LLP investigates whether Deciphera Pharmaceuticals, Inc. has obtained a Fair Price in its transaction with ONO Pharmaceutical Co.

Deciphera Catapults 72% After Ono Pharmaceutical Agrees To Buy It For $2.4 Billion